Bernhard J. Eigl

10.5k citations
107 papers · 7.7k · 7 hit papers · h-index 33

Impact in

    • Prostate Cancer Treatment and Research
    • Renal cell carcinoma treatment
    • Prostate Cancer Diagnosis and Treatment
  • Oncology top 1%
    • Cancer Immunotherapy and Biomarkers
    • Inflammatory Biomarkers in Disease Prognosis

Papers in

    • Prostate Cancer Treatment and Research 37
    • Renal cell carcinoma treatment 6
    • Bladder and Urothelial Cancer Treatments 30
    • Genital Health and Disease 6
    • Testicular diseases and treatments 3

Bernhard J. Eigl

104 papers receiving 7.5k citations

Bernhard J. Eigl's Hit Papers

Prediction of plasma ctDNA fraction and prognostic implications of liquid biopsy in advanced prostate cancer 2024 · 96 citations
960+5+11Years since publication5001k1.5k

Peers

Bernhard J. Eigl
Comparison fields: 5 of 98
  • Pulmonary and Respiratory Medicine 3.4k
  • Oncology 1.8k
  • Surgery 1.9k
  • Cancer Research 596
  • Molecular Biology 515
Replace Yasushi Omuro with:
Yasushi Omuro Japan
Julie Hill China
Jae Moon Bae South Korea
Ronan Joseph Kelly United States
Inderpal S. Sarkaria United States
Aaron R. Sasson United States
Harry H. Yoon United States
Hisato Kawakami Japan
María Alsina Spain
Ellis Glenn Levine United States
Bernhard J. Eigl relative to Yasushi Omuro Japan Yasushi Omuro's profile →
Citations per field
00.5×1.5×2.2×
Yasushi Omuro · 1×
Citations per year

Countries citing papers authored by Bernhard J. Eigl

Since Specialization
Citations

This map shows the geographic impact of Bernhard J. Eigl's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Bernhard J. Eigl with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Bernhard J. Eigl more than expected).

Fields of papers citing papers by Bernhard J. Eigl

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Bernhard J. Eigl. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Bernhard J. Eigl. The network helps show where Bernhard J. Eigl may publish in the future.

Co-authors

The 25 scholars most cited alongside Bernhard J. Eigl, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Bernhard J. Eigl Line = papers co-authored together Bernhard J. Eigl links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown

Showing the 20 most-cited of 107 papers — load more, or switch the sort, to bring in the rest.

#Work
1
Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial
Hit paper breakdown →
20161820
2
Prognostic Factors for Overall Survival in Patients With Metastatic Renal Cell Carcinoma Treated With Vascular Endothelial Growth Factor–Targeted Agents: Results From a Large, Multicenter Study
Hit paper breakdown →
20091741
3
Circulating Tumor DNA Genomics Correlate with Resistance to Abiraterone and Enzalutamide in Prostate Cancer
Hit paper breakdown →
2018442
4
Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial
Hit paper breakdown →
2020408
5
Optimal sequencing of enzalutamide and abiraterone acetate plus prednisone in metastatic castration-resistant prostate cancer: a multicentre, randomised, open-label, phase 2, crossover trial
Hit paper breakdown →
2019273
6
Perioperative Durvalumab with Neoadjuvant Chemotherapy in Operable Bladder Cancer
Hit paper breakdown →
2024198
7 2010193
8 2013151
9 2015151
10 2014143
11 2017139
12 2021135
13 2011104
14 200597
15
Prediction of plasma ctDNA fraction and prognostic implications of liquid biopsy in advanced prostate cancer
Hit paper breakdown →
202496
16 201694
17 202175
18 200866
19 201863
20 201560

About Bernhard J. Eigl

Bernhard J. Eigl is a scholar working on Pulmonary and Respiratory Medicine, Surgery, Cancer Research, Oncology and Molecular Biology, having authored 107 papers that have together received 7.7k indexed citations. Recurring topics across this work include Prostate Cancer Treatment and Research (37 papers), Bladder and Urothelial Cancer Treatments (30 papers), Cancer Genomics and Diagnostics (8 papers), Genital Health and Disease (6 papers), Renal cell carcinoma treatment (6 papers), Cancer Immunotherapy and Biomarkers (3 papers), Testicular diseases and treatments (3 papers) and MicroRNA in disease regulation (3 papers). The work is most often cited by research in Pulmonary and Respiratory Medicine (3.4k citations), Oncology (1.8k citations), Surgery (1.9k citations), Cancer Research (596 citations) and Molecular Biology (515 citations). Bernhard J. Eigl has collaborated with scholars based in Canada, United States and Italy. Frequent co-authors include Kim N. Chi, Christian Kollmannsberger, Scott A. North, Martin Edwin Gleave, Arun Azad, Daniel Y.C. Heng, Peter M. Venner, Joseph D. Ruether, Mark Andrew Warren and Jennifer Jane Knox. Their work appears in journals such as Annals of Oncology, Clinical Cancer Research, Clinical Genitourinary Cancer, European Urology and The Journal of Urology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact